Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00671671 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT00671671: Completed Phase 1 study, sponsored by Pfizer.

NCT00671671 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00671671, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.

Primary Outcome

Plasma HCV RNA levels were quantified using the Abbott RealTime HCV assay (lower limit of quantification \[LLOQ\] = 12 international unit per milliliter \[IU/mL\]). Baseline value calculated as an average of screening, Day 0 and Day 1 (0 hour) measurements. Change from baseline in plasma log10 HCV RNA was calculated for all participants after the last day of dosing (Day 11 for Cohort A).

Interventions

  • DRUG Small Molecule Agent (PF-868554)

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-04
Est. Completion 2008-12
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT00671671 record still lists

NCT00671671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 1 intervention - of which Small Molecule Agent (PF-868554) is the first listed.

NCT00671671 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00671671 about?

NCT00671671 is a clinical study titled "Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.". Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.

What is the current status of trial NCT00671671?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-04. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00671671?

The interventions under investigation include: Small Molecule Agent (PF-868554) (DRUG).

Who is sponsoring clinical trial NCT00671671?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00671671's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00671671, the US trial registry maintained by the National Library of Medicine. NCT00671671 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.